TBPH Theravance Corp: Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

Geopolitical risks and patent complexities are weighing on Theravance Biopharma (TBPH), although the diversification of its respiratory portfolio and royalty streams stabilize the business. On the GURU.Markets platform, the EV/EBITDA valuation history helps balance these factors, with the metric holding around 70.75. Ultimately, while loyalty among COPD patients remains high, pricing pressure from generics is eroding the company's overall margins.
Rincian metrik komprehensif lan analitis Theravance (TBPH)

This ratio compares the total enterprise value, including net debt, to operating profit before depreciation and amortization, allowing for an assessment of the real value of assets regardless of the tax regime. By analyzing the EV/EBITDA metric of Theravance Biopharma (TBPH), an investor determines the efficiency of capitalizing the company's scientific achievements in respiratory therapy, where a strong reputation in pulmonology should convert into sustainable growth in operating cash flow.